Banque Pictet & Cie’s NovoCure NVCR Stock Holding History

Banque Pictet & Cie’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-162,467	Closed	-$2.43M	–	372
2023 Q4	$2.43M	Buy	162,467 +124,967	+333%	+$1.67M	0.02%	194
2023 Q3	$606K	Sell	37,500 -20,805	-36%	-$600K	0.01%	316
2023 Q2	$2.42M	Buy	58,305 +25,985	+80%	+$1.61M	0.02%	229
2023 Q1	$1.94M	Sell	32,320 -28,087	-46%	-$2.24M	0.02%	281
2022 Q4	$4.43M	Buy	60,407 +29,778	+97%	+$2.24M	0.05%	195
2022 Q3	$2.33M	Sell	30,629 -44,797	-59%	-$3.49M	0.03%	262
2022 Q2	$5.24K	Buy	75,426 +23,503	+45%	+$1.77M	0.05%	171
2022 Q1	$4.3M	Sell	51,923 -248,049	-83%	-$18.3M	0.03%	202
2021 Q4	$22.5M	Buy	+299,972	New	+$30.1M	0.17%	75

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Banque Pictet & Cie's NVCR Position: Q1 2024 in Review

Banque Pictet & Cie sold out of NovoCure (NVCR) in Q1 2024, closing a stake of 162,467 shares — an estimated $2.43M sold.

Banque Pictet & Cie first reported a position in NVCR in Q4 2021 and held it in 9 quarters. The position peaked at $22.5M in Q4 2021. 237 funds tracked by Wall St. Rank hold NVCR as of Q1 2024.

Banque Pictet & Cie reported no remaining NovoCure position as of Q1 2024 after selling out during the quarter.
Banque Pictet & Cie sold 162,467 NovoCure shares in Q1 2024, an estimated $2.43M.
Banque Pictet & Cie first reported a position in NovoCure in Q4 2021 and held it in 9 quarters.
Banque Pictet & Cie's NovoCure position peaked at $22.5M in Q4 2021.
237 funds tracked by Wall St. Rank held NovoCure as of Q1 2024.

Based on Banque Pictet & Cie's 13F filing for Q1 2024, filed 6 May 2024.